featured
Brentuximab Vedotin Plus Cyclophosphamide, Doxorubicin, Etoposide, and Prednisone Followed by Brentuximab Vedotin Consolidation for CD30-Positive Peripheral T-Cell Lymphomas
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Additional Info
Disclosure statements are available on the authors' profiles:
The Lancet Haematology
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.
Brentuximab vedotin plus cyclophosphamide, doxorubicin, etoposide, and prednisone followed by brentuximab vedotin consolidation in CD30-positive peripheral T-cell lymphomas: a multicentre, single-arm, phase 2 study
Lancet Haematol 2024 Jul 24;[EPub Ahead of Print], AF Herrera, J Zain, KJ Savage, T Feldman, JE Brammer, L Chen, S Puverel, L Popplewell, LE Budde, M Mei, C Hosing, R Nair, L Leslie, S Daniels, L Peters, S Forman, S Rosen, L Kwak, SP IyerFrom MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.